Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Sunday, May 19, 2024 · 712,842,023 Articles · 3+ Million Readers

Hamilton Thorne to Announce Q1 2024 Financial Results and Hold Conference Call on May 14, 2024

/EIN News/ -- BEVERLY, Mass. and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three months ended March 31, 2024 before market open on Tuesday, May 14, 2024. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedar.com.

The Company will follow with a conference call on the same day at 9:00 a.m. EDT to review highlights of the results.

All interested parties are welcome to join the conference call by dialing toll free 1-833-366-1126 in North America, or 1-412-317-0703 from other locations, and requesting the “Hamilton Thorne Conference Call.” The Company’s updated investor presentation and a recording of the call will be available on Hamilton Thorne’s website shortly after the call.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, laboratory equipment, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, Gynetics, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne Ltd.’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX, nor its regulation services provider (as that term is defined in the policies of the TSX), accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Kate Torchilin, Pres. & CEO Francesco Fragasso, CFO Glen Akselrod
Hamilton Thorne Ltd. Hamilton Thorne Ltd. Bristol Investor Relations
978-921-2050 978-921-2050 905-326-1888
ir@hamiltonthorne.ltd ir@hamiltonthorne.ltd glen@bristolir.com


Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release